{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T03:28:46Z","timestamp":1786678126861,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Key Research and Development Program of Zhejiang province","award":["2023C03057"],"award-info":[{"award-number":["2023C03057"]}]},{"name":"the Zhejiang Leading Talent Entrepreneurship Project","award":["2021R02019"],"award-info":[{"award-number":["2021R02019"]}]},{"name":"the Key Technology Innovation Projects of Jiaxing","award":["2024BZ20002"],"award-info":[{"award-number":["2024BZ20002"]}]},{"name":"the Jiaxing Leading Talent Entrepreneurship Project"},{"name":"the Jiaxing Key Disciplines Project","award":["2023-ZC-013"],"award-info":[{"award-number":["2023-ZC-013"]}]},{"name":"Jiaxing Key Laboratory","award":["2020-mnzdsys"],"award-info":[{"award-number":["2020-mnzdsys"]}]},{"name":"the Natural Science Foundation of Zhejiang pvovince, China","award":["LTGD24H050001"],"award-info":[{"award-number":["LTGD24H050001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16249-y","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T06:16:00Z","timestamp":1780899360000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrating DNA methylation and clinical features to predict prostate cancer prognosis"],"prefix":"10.1186","volume":"26","author":[{"given":"Yi","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenxuan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhua","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyu","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2881-2281","authenticated-orcid":false,"given":"Jieyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokai","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziying","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"issue":"4","key":"16249_CR1","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s12253-015-9917-8","volume":"21","author":"Z Mostafavi-Pour","year":"2015","unstructured":"Mostafavi-Pour Z, Kianpour S, Dehghani M, et al. Methylation of integrin \u03b14 and E-cadherin genes in human prostate cancer. Pathol Oncol Res. 2015;21(4):921\u20137. https:\/\/doi.org\/10.1007\/s12253-015-9917-8.","journal-title":"Pathol Oncol Res"},{"issue":"1","key":"16249_CR2","first-page":"161","volume":"36","author":"K Ramachandran","year":"2016","unstructured":"Ramachandran K, Speer C, Nathanson L, et al. Role of DNA methylation in cabazitaxel resistance in prostate cancer. Anticancer Res. 2016;36(1):161\u20138.","journal-title":"Anticancer Res"},{"issue":"5","key":"16249_CR3","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/bjc.2015.7","volume":"112","author":"TA Jatkoe","year":"2015","unstructured":"Jatkoe TA, Karnes RJ, Freedland SJ, et al. A urine-based methylation signature for risk stratification within low-risk prostate cancer. Br J Cancer. 2015;112(5):802\u20138. https:\/\/doi.org\/10.1038\/bjc.2015.7.","journal-title":"Br J Cancer"},{"issue":"10","key":"16249_CR4","doi-asserted-by":"publisher","first-page":"10449","DOI":"10.1007\/s13277-014-2300-7","volume":"35","author":"D Jiang","year":"2014","unstructured":"Jiang D, Shen Y, Dai D, et al. Meta-analyses of methylation markers for prostate cancer. Tumour Biol. 2014;35(10):10449\u201355. https:\/\/doi.org\/10.1007\/s13277-014-2300-7.","journal-title":"Tumour Biol"},{"issue":"3","key":"16249_CR5","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4111\/kju.2013.54.3.194","volume":"54","author":"H-Y Yoon","year":"2013","unstructured":"Yoon H-Y, Kim Y-W, Kang HW, et al. Pyrosequencing analysis of APC methylation level in human prostate tissues: a molecular marker for prostate cancer. Korean J Urol. 2013;54(3):194\u20138. https:\/\/doi.org\/10.4111\/kju.2013.54.3.194.","journal-title":"Korean J Urol"},{"issue":"3","key":"16249_CR6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s13148-020-00912-5","volume":"12","author":"Y Gao","year":"2020","unstructured":"Gao Y, et al. DNA methylation and prostate cancer: a review[J]. J Epigenetics Res. 2020;12(3):245\u201363. https:\/\/doi.org\/10.1007\/s13148-020-00912-5.","journal-title":"J Epigenetics Res"},{"issue":"3","key":"16249_CR7","first-page":"206","volume":"18","author":"TA Bishop","year":"2015","unstructured":"Bishop TA, et al. DNA methylation in prostate cancer: a review of the literature. Prostate Cancer Prostatic Dis. 2015;18(3):206\u201313.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"16249_CR8","first-page":"401","volume":"70","author":"R B\u00f6ttcher","year":"2016","unstructured":"B\u00f6ttcher R, et al. Methylation of prostate cancer-related genes in serum DNA as a diagnostic tool. Eur Urol. 2016;70(3):401\u201310.","journal-title":"Eur Urol"},{"issue":"3","key":"16249_CR9","first-page":"171","volume":"30","author":"A Kumar","year":"2018","unstructured":"Kumar A, et al. Epigenetic regulation of prostate cancer. Curr Opin Oncol. 2018;30(3):171\u20137.","journal-title":"Curr Opin Oncol"},{"issue":"9","key":"16249_CR10","first-page":"556","volume":"12","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, et al. The role of DNA methylation in prostate cancer. Nat Rev Urol. 2015;12(9):556\u201364.","journal-title":"Nat Rev Urol"},{"issue":"3","key":"16249_CR11","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1158\/0008-5472.CAN-03-2592","volume":"64","author":"C Ren","year":"2004","unstructured":"Ren C, Li L, Yang G, et al. RTVP-1, a tumor suppressor inactivated by methylation in prostate cancer. Cancer Res. 2004;64(3):969\u201376.","journal-title":"Cancer Res"},{"key":"16249_CR12","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1186\/1471-2407-14-655","volume":"14","author":"N Vasiljevi\u0107","year":"2014","unstructured":"Vasiljevi\u0107 N, Ahmad AS, Thorat MA, et al. DNA methylation gene-based models indicating independent poor outcome in prostate cancer. BMC Cancer. 2014;14:655. https:\/\/doi.org\/10.1186\/1471-2407-14-655.","journal-title":"BMC Cancer"},{"key":"16249_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/(SICI)1097-0045(1996)6+<36::AID-PROS8>3.0.CO;2-I","volume":"6","author":"DF Jarrard","year":"1996","unstructured":"Jarrard DF, Bova GS, Isaacs WB. DNA methylation, molecular genetic, and linkage studies in prostate cancer. Prostate Suppl. 1996;6:36\u201344.","journal-title":"Prostate Suppl"},{"key":"16249_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4137\/BIC.S3187","volume":"2","author":"H Ahmed","year":"2010","unstructured":"Ahmed H. Promoter methylation in prostate cancer and its application for the early detection of prostate cancer using serum and urine samples. Biomark Cancer. 2010;2:17\u201333. https:\/\/doi.org\/10.4137\/BIC.S3187.","journal-title":"Biomark Cancer"},{"issue":"3","key":"16249_CR15","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.juro.2009.05.003","volume":"182","author":"J Baden","year":"2009","unstructured":"Baden J, Green G, Painter J, et al. Multicenter evaluation of an investigational prostate cancer methylation assay. J Urol. 2009;182(3):1186\u201393. https:\/\/doi.org\/10.1016\/j.juro.2009.05.003.","journal-title":"J Urol"},{"issue":"1","key":"16249_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.canlet.2010.12.010","volume":"302","author":"SJ Kim","year":"2011","unstructured":"Kim SJ, Kelly WK, Fu A, et al. Genome-wide methylation analysis identifies involvement of TNF-\u03b1 mediated cancer pathways in prostate cancer. Cancer Lett. 2011;302(1):47\u201353. https:\/\/doi.org\/10.1016\/j.canlet.2010.12.010.","journal-title":"Cancer Lett"},{"issue":"10","key":"16249_CR17","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1002\/ijc.25908","volume":"129","author":"L Liu","year":"2011","unstructured":"Liu L, Kron KJ, Pethe VV, et al. Association of tissue promoter methylation levels of APC, TGF\u03b22, HOXD3 and RASSF1A with prostate cancer progression. Int J Cancer. 2011;129(10):2454\u201362. https:\/\/doi.org\/10.1002\/ijc.25908.","journal-title":"Int J Cancer"},{"issue":"13","key":"16249_CR18","doi-asserted-by":"publisher","first-page":"4523","DOI":"10.1158\/1078-0432.CCR-10-2817","volume":"17","author":"Y-J Kim","year":"2011","unstructured":"Kim Y-J, Yoon H-Y, Kim S-K, et al. EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling. Clin Cancer Res. 2011;17(13):4523\u201330. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2817.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"16249_CR19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/ijc.23890","volume":"124","author":"M Guan","year":"2009","unstructured":"Guan M, Xu C, Zhang F, Ye C. Aberrant methylation of EphA7 in human prostate cancer and its relation to clinicopathologic features. Int J Cancer. 2009;124(1):88\u201394. https:\/\/doi.org\/10.1002\/ijc.23890.","journal-title":"Int J Cancer"},{"issue":"2","key":"16249_CR20","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1677\/erc.1.01184","volume":"13","author":"AS Perry","year":"2006","unstructured":"Perry AS, Foley R, Woodson K, Lawler M. The emerging roles of DNA methylation in the clinical management of prostate cancer. Endocr Relat Cancer. 2006;13(2):357\u201377.","journal-title":"Endocr Relat Cancer"},{"issue":"18","key":"16249_CR21","doi-asserted-by":"publisher","first-page":"6582","DOI":"10.1158\/1078-0432.CCR-05-0658","volume":"11","author":"H Enokida","year":"2005","unstructured":"Enokida H, Shiina H, Urakami S, et al. Multigene methylation analysis for detection and staging of prostate cancer. Clin Cancer Res. 2005;11(18):6582\u20138.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"16249_CR22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/pcan.2012.47","volume":"16","author":"N Vasiljevi\u0107","year":"2013","unstructured":"Vasiljevi\u0107 N, Ahmad AS, Beesley C, et al. Association between DNA methylation of HSPB1 and death in low Gleason score prostate cancer. Prostate Cancer Prostatic Dis. 2013;16(1):35\u201340. https:\/\/doi.org\/10.1038\/pcan.2012.47.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"10","key":"16249_CR23","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1038\/sj.bjc.6603767","volume":"96","author":"AS Perry","year":"2007","unstructured":"Perry AS, Loftus B, Moroose R, et al. In silico mining identifies IGFBP3 as a novel target of methylation in prostate cancer. Br J Cancer. 2007;96(10):1587\u201394.","journal-title":"Br J Cancer"},{"issue":"1","key":"16249_CR24","first-page":"35","volume":"57","author":"JB Nelson","year":"1997","unstructured":"Nelson JB, Lee WH, Nguyen SH, et al. Methylation of the 5\u2019 CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res. 1997;57(1):35\u20137.","journal-title":"Cancer Res"},{"issue":"7943","key":"16249_CR25","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41586-022-05580-6","volume":"613","author":"N Loyfer","year":"2023","unstructured":"Loyfer N, Magenheim J, Peretz A, et al. A DNA methylation atlas of normal human cell types. Nature. 2023;613(7943):355\u201364. https:\/\/doi.org\/10.1038\/s41586-022-05580-6.","journal-title":"Nature"},{"issue":"3","key":"16249_CR26","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41592-022-01412-7","volume":"19","author":"T Zhu","year":"2022","unstructured":"Zhu T, Liu J, Beck S, et al. A pan-tissue DNA methylation atlas enables in silico decomposition of human tissue methylomes at cell-type resolution. Nat Methods. 2022;19(3):296\u2013306. https:\/\/doi.org\/10.1038\/s41592-022-01412-7.","journal-title":"Nat Methods"},{"issue":"1","key":"16249_CR27","doi-asserted-by":"publisher","first-page":"7694","DOI":"10.1038\/s41467-022-35320-3","volume":"13","author":"X Zhou","year":"2022","unstructured":"Zhou X, Cheng Z, Dong M, et al. Tumor fractions deciphered from circulating cell-free DNA methylation for cancer early diagnosis. Nat Commun. 2022;13(1):7694. https:\/\/doi.org\/10.1038\/s41467-022-35320-3.","journal-title":"Nat Commun"},{"issue":"7","key":"16249_CR28","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41571-018-0004-4","volume":"15","author":"A Koch","year":"2018","unstructured":"Koch A, Joosten SC, Feng Z, et al. Analysis of DNA methylation in cancer: location revisited. Nat Rev Clin Oncol. 2018;15(7):459\u201366. https:\/\/doi.org\/10.1038\/s41571-018-0004-4.","journal-title":"Nat Rev Clin Oncol"},{"issue":"18","key":"16249_CR29","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1038\/s41388-018-0660-y","volume":"38","author":"M Panagopoulou","year":"2019","unstructured":"Panagopoulou M, Karaglani M, Balgkouranidou I, et al. Circulating cell-free DNA in breast cancer: size profiling, levels, and methylation patterns lead to prognostic and predictive classifiers. Oncogene. 2019;38(18):3387\u2013401. https:\/\/doi.org\/10.1038\/s41388-018-0660-y.","journal-title":"Oncogene"},{"issue":"6","key":"16249_CR30","doi-asserted-by":"publisher","first-page":"6917","DOI":"10.3892\/ol.2019.11015","volume":"18","author":"KA Nekrasov","year":"2019","unstructured":"Nekrasov KA, Vikarchuk MV, Rudenko EE, et al. 6-gene promoter methylation assay is potentially applicable for prostate cancer clinical staging based on urine collection following prostatic massage. Oncol Lett. 2019;18(6):6917\u201325. https:\/\/doi.org\/10.3892\/ol.2019.11015.","journal-title":"Oncol Lett"},{"issue":"4","key":"16249_CR31","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1172\/JCI131041","volume":"130","author":"H Beltran","year":"2020","unstructured":"Beltran H, Romanel A, Conteduca V, et al. Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. J Clin Invest. 2020;130(4):1653\u201368. https:\/\/doi.org\/10.1172\/JCI131041.","journal-title":"J Clin Invest"},{"key":"16249_CR32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13148-018-0524-x","volume":"10","author":"I Brikun","year":"2018","unstructured":"Brikun I, Nusskern D, Decatus A, et al. A panel of DNA methylation markers for the detection of prostate cancer from FV and DRE urine DNA. Clin Epigenetics. 2018;10:91. https:\/\/doi.org\/10.1186\/s13148-018-0524-x.","journal-title":"Clin Epigenetics"},{"key":"16249_CR33","doi-asserted-by":"publisher","unstructured":"Larsen LK, Lind GE, Guldberg P, Dahl C. DNA-methylation-based detection of urological cancer in urine: overview of biomarkers and considerations on biomarker design, source of DNA, and detection technologies. Int J Mol Sci. 2019;20(11). https:\/\/doi.org\/10.3390\/ijms20112657.","DOI":"10.3390\/ijms20112657"},{"issue":"7801","key":"16249_CR34","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41586-020-2135-x","volume":"580","author":"J Li","year":"2020","unstructured":"Li J, Xu C, Lee HJ, et al. A genomic and epigenomic atlas of prostate cancer in Asian populations. Nature. 2020;580(7801):93\u20139. https:\/\/doi.org\/10.1038\/s41586-020-2135-x.","journal-title":"Nature"},{"key":"16249_CR35","doi-asserted-by":"publisher","DOI":"10.1200\/PO.18.00134","author":"E O\u2019Reilly","year":"2019","unstructured":"O\u2019Reilly E, Tuzova AV, Walsh AL, et al. epiCaPture: a urine DNA methylation test for early detection of aggressive prostate cancer. JCO Precis Oncol. 2019. https:\/\/doi.org\/10.1200\/PO.18.00134.","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"16249_CR36","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13148-018-0575-z","volume":"10","author":"F Zhao","year":"2018","unstructured":"Zhao F, Olkhov-Mitsel E, Kamdar S, et al. A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer. Clin Epigenetics. 2018;10(1):147. https:\/\/doi.org\/10.1186\/s13148-018-0575-z.","journal-title":"Clin Epigenetics"},{"key":"16249_CR37","unstructured":"Zhang DY, Gong ZY, Fu HY et al. DNA methylation site combination as biomarker for prostate cancer and its application. China Patent 202310247009. Filed March 15, 2023. Published February 26, 2025."},{"key":"16249_CR38","unstructured":"Ruan W, Huang J, Lin T et al. DNA methylation biomarker combination and detection kit related to bladder cancer. Chinese Patent No. CN110923322A. Granted: March 27, 2020."},{"key":"16249_CR39","unstructured":"Fan J, Chen Z, Ruan W. Reagent kit and method for detecting prognosis of prostate cancer. Chinese Patent Application No. CN110578004A. Filed: December 8, 2020."},{"issue":"12","key":"16249_CR40","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1593\/neo.07760","volume":"9","author":"T Kawasaki","year":"2007","unstructured":"Kawasaki T, Nosho K, Ohnishi M, et al. IGFBP3 promoter methylation in colorectal cancer: relationship with microsatellite instability, CpG island methylator phenotype, and p53. Neoplasia. 2007;9(12):1091\u20138. https:\/\/doi.org\/10.1593\/neo.07760.","journal-title":"Neoplasia"},{"issue":"1","key":"16249_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-017-0604-0","volume":"16","author":"J Torres-Ferreira","year":"2017","unstructured":"41, Torres-Ferreira J, Ramalho-Carvalho J, Gomez A, et al. MiR-193b promoter methylation accurately detects prostate cancer in urine sediments and miR-34b\/c or miR-129-2 promoter methylation define subsets of clinically aggressive tumors. Mol Cancer. 2017;16(1):1\u201312. https:\/\/doi.org\/10.1186\/s12943-017-0604-0.","journal-title":"Mol Cancer"},{"issue":"10","key":"16249_CR42","doi-asserted-by":"publisher","first-page":"e46297","DOI":"10.1371\/journal.pone.0046297","volume":"7","author":"R Thomas","year":"2012","unstructured":"Thomas R, Michael B, Anders C, et al. Diagnosis of bladder cancer recurrence based on urinary levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 hypermethylation. PLoS ONE. 2012;7(10):e46297. https:\/\/doi.org\/10.1371\/journal.pone.0046297.","journal-title":"PLoS ONE"},{"issue":"2","key":"16249_CR43","doi-asserted-by":"publisher","first-page":"e1867","DOI":"10.1097\/JU.0000000000001867","volume":"206","author":"A Atala","year":"2021","unstructured":"Atala A. Comment on: Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer. J Urol. 2021;206(2):e1867. https:\/\/doi.org\/10.1097\/JU.0000000000001867.","journal-title":"J Urol"},{"issue":"1","key":"16249_CR44","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/JU.0000000000003491","volume":"210","author":"JT Wei","year":"2023","unstructured":"Wei JT, Barocas D, Carlsson S, et al. Early detection of prostate cancer: AUA\/SUO guideline part I: Prostate cancer screening. J Urol. 2023;210(1):46\u201353. https:\/\/doi.org\/10.1097\/JU.0000000000003491.","journal-title":"J Urol"},{"issue":"2","key":"16249_CR45","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1177\/1756287211400496","volume":"3","author":"E Chiong","year":"2011","unstructured":"Chiong E, Yap NY. The value of prostate-specific antigen in Asia. Ther Adv Urol. 2011;3(2):77\u201383. https:\/\/doi.org\/10.1177\/1756287211400496.","journal-title":"Ther Adv Urol"},{"issue":"2","key":"16249_CR46","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/bju.12368","volume":"113","author":"PF Pinsky","year":"2014","unstructured":"Pinsky PF, Parnes HL, Andriole G. Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial. BJU Int. 2014;113(2):254\u20139. https:\/\/doi.org\/10.1111\/bju.12368.","journal-title":"BJU Int"},{"issue":"9959","key":"16249_CR47","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","volume":"384","author":"FH Schr\u00f6der","year":"2014","unstructured":"Schr\u00f6der FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027\u201335. https:\/\/doi.org\/10.1016\/S0140-6736(14)60525-0.","journal-title":"Lancet"},{"issue":"9","key":"16249_CR48","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1001\/jama.2018.0154","volume":"319","author":"RM Martin","year":"2018","unstructured":"Martin RM, Donovan JL, Turner EL, et al. Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial. JAMA. 2018;319(9):883\u201395. https:\/\/doi.org\/10.1001\/jama.2018.0154.","journal-title":"JAMA"},{"issue":"2","key":"16249_CR49","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.eururo.2006.12.031","volume":"52","author":"G Guichard","year":"2007","unstructured":"Guichard G, Larr\u00e9 S, Gallina A, et al. Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients. Eur Urol. 2007;52(2):430\u20135. https:\/\/doi.org\/10.1016\/j.eururo.2006.12.031.","journal-title":"Eur Urol"},{"issue":"5","key":"16249_CR50","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.eururo.2018.07.031","volume":"74","author":"AR Alberts","year":"2018","unstructured":"Alberts AR, Roobol MJ, Drost FJH, et al. Risk-stratification based on MRI-ERSPC-RC reduces unnecessary biopsies in prostate cancer screening. Eur Urol. 2018;74(5):562\u20138. https:\/\/doi.org\/10.1016\/j.eururo.2018.07.031.","journal-title":"Eur Urol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16249-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16249-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16249-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T02:59:32Z","timestamp":1786676372000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16249-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16249"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16249-y","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"19 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Institutional Review Board of the Affiliated Hospital of Jiaxing University (2022-KY-127) and was performed according to the Helsinki Declaration. Additionally, written informed consent was obtained from all participants.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for publication was obtained from all participants.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"981"}}